Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants

Abstract As part of a multicenter study evaluating homologous and heterologous COVID-19 booster vaccines, we assessed the magnitude, breadth, and short-term durability of binding and pseudovirus-neutralizing antibody (PsVNA) responses following a single booster dose of NVX-CoV2373 in adults primed w...

Full description

Bibliographic Details
Main Authors:	Kirsten E. Lyke, Robert L. Atmar, Clara Dominguez Islas, Christine M. Posavad, Meagan E. Deming, Angela R. Branche, Christine Johnston, Hana M. El Sahly, Srilatha Edupuganti, Mark J. Mulligan, Lisa A. Jackson, Richard E. Rupp, Christina A. Rostad, Rhea N. Coler, Martín Bäcker, Angelica C. Kottkamp, Tara M. Babu, David Dobrzynski, Judith M. Martin, Rebecca C. Brady, Robert W. Frenck, Kumaravel Rajakumar, Karen Kotloff, Nadine Rouphael, Daniel Szydlo, Rahul PaulChoudhury, Janet I. Archer, Sonja Crandon, Brian Ingersoll, Amanda Eaton, Elizabeth R. Brown, M. Juliana McElrath, Kathleen M. Neuzil, David S. Stephens, Diane J. Post, Bob C. Lin, Leonid Serebryannyy, John H. Beigel, David C. Montefiori, Paul C. Roberts, the DMID 21-0012 Study Group
Format:	Article
Language:	English
Published:	Nature Portfolio 2023-07-01
Series:	npj Vaccines
Online Access:	https://doi.org/10.1038/s41541-023-00693-z

Similar Items

Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine
by: Eddie Underwood, et al.
Published: (2023-12-01)

Safety and efficacy of NVX-CoV2373 Covid-19 vaccine
by: Heath, PT, et al.
Published: (2021)

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages
by: Jinal N. Bhiman, et al.
Published: (2023-01-01)

Protein vaccine NVX-CoV2373 elicits functional T cell immunity
by: Pengcheng Zhou
Published: (2022-10-01)

Myopericarditis following both BNT162b2 and NVX-CoV2373
by: Saima Ahmad, et al.
Published: (2022-12-01)

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
by: Jing-Hui Tian, et al.
Published: (2021-01-01)

Angioedema‐like eyelid edema following the second NVX‐CoV2373 COVID‐19 vaccination
by: Mari Matsumoto, et al.
Published: (2023-10-01)

Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines
by: Toback, S, et al.
Published: (2021)

NVX-CoV2373 induces humoral and cellular immune responses that are functionally comparable to vector and mRNA-based vaccines
by: Franz Mai, et al.
Published: (2024-03-01)

NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4+ and CD8+ T cell responses
by: Carolyn Rydyznski Moderbacher, et al.
Published: (2022-10-01)

Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
by: Matthew J. Gorman, et al.
Published: (2021-09-01)

Safety and efficacy of the NVX-CoV2373 coronavirus disease 2019 vaccine at completion of the placebo-controlled phase of a randomized controlled trial
by: Heath, PT, et al.
Published: (2022)

Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
by: Lauffenburger, Douglas
Published: (2023)

Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines
by: Anthony M. Marchese, et al.
Published: (2023-12-01)

NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines
by: Magdalena Mueller-Enz, et al.
Published: (2023-07-01)

Myopericarditis Associated with the Novavax COVID-19 Vaccine (NVX-CoV2373): A Retrospective Analysis of Individual Case Safety Reports from VigiBase
by: Diego Macías Saint-Gerons, et al.
Published: (2023-02-01)

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
by: Neil Formica, et al.
Published: (2021-10-01)

Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled studyResearch in context
by: Prasad S. Kulkarni, et al.
Published: (2023-03-01)

Cytokine and Chemokine Production in Mice Inoculated with NVX-CoV2373 (Nuvaxovid<sup>®</sup>) in Comparison with Omicron BA.4/5 Bivalent BNT162b2 (Comirnaty<sup>®</sup>)
by: Tetsuo Nakayama, et al.
Published: (2023-11-01)

2373
by: Serena-Kaye Kinley-Cooper, et al.
Published: (2017-09-01)

Treatment of Swine Closed Head Injury with Perfluorocarbon NVX-428
by: Francoise Arnaud, et al.
Published: (2020-09-01)

Effects of Topically Applied Betulinic Acid and NVX-207 on Melanocytic Tumors in 18 Horses
by: Lisa A. Weber, et al.
Published: (2021-11-01)

SARS-CoV-2 infection and immune responses
by: Rakhi Harne, et al.
Published: (2023-03-01)

NVX-412, a new oncology drug candidate, induces S-phase arrest and DNA damage in cancer cells in a p53-independent manner.
by: Alexandra Hebar, et al.
Published: (2012-01-01)

PB2373: A SINGLE-CELL ATLAS OF HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMA
by: Xiaomei Zhang, et al.
Published: (2023-08-01)

Correlates of Vaccine-Induced Protection against SARS-CoV-2
by: Till Koch, et al.
Published: (2021-03-01)

Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation
by: Yunda Huang, et al.
Published: (2021-12-01)

In vitro assessment of triterpenoids NVX-207 and betulinyl-bis-sulfamate as a topical treatment for equine skin cancer.
by: Lisa Annabel Weber, et al.
Published: (2020-01-01)

Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera
by: Binh Ha, et al.
Published: (2021-10-01)

An evaluation of cytokine and cellular immune responses to heterologous prime-boost vaccination with influenza A/H7N7-A/H7N9 inactivated vaccine
by: Hana M El Sahly, et al.
Published: (2020-12-01)

HSV-2-Specific Human Female Reproductive Tract Tissue Resident Memory T Cells Recognize Diverse HSV Antigens
by: David M. Koelle, et al.
Published: (2022-03-01)

Differential Tropism of SARS-CoV and SARS-CoV-2 in Bat Cells
by: Susanna K.P. Lau, et al.
Published: (2020-12-01)

Defining the pediatric response to SARS-CoV-2 variants
by: Reanne M. Ho, et al.
Published: (2023-05-01)

Myopathy associated with severe SARS-CoV-2 infection
by: M.J. Abenza Abildúa, et al.
Published: (2020-11-01)

Enhanced Remdesivir Analogues to Target SARS-CoV-2
by: Ryuichi Majima, et al.
Published: (2023-03-01)

SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions
by: T.M. Abdelghany, et al.
Published: (2021-03-01)

SARS-CoV-2 and Risk to Food Safety
by: Lucia E. C. M. Anelich, et al.
Published: (2020-11-01)

Prenatal Exposure to SARS-Cov-2 and Schizophrenia Development: What to Expect?
by: F. Tavares, et al.
Published: (2022-06-01)

In-Flight Transmission of SARS-CoV-2
by: Edward M. Choi, et al.
Published: (2020-11-01)

Global variation in sequencing impedes SARS-CoV-2 surveillance.
by: Dana C Crawford, et al.
Published: (2021-07-01)